Мақаланы E-mail арқылы жіберу Synthesis of (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside
- Авторлар: Khalikova M.J.1, Roziqov U.A.1, Skrylkova A.S.2, Egorov D.M.2, Safarov S.S.1
-
Мекемелер:
- V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
- St. Petersburg State Institute of Technology (Technical University)
- Шығарылым: Том 60, № 4 (2024)
- Беттер: 516-522
- Бөлім: Articles
- URL: https://bakhtiniada.ru/0514-7492/article/view/278013
- DOI: https://doi.org/10.31857/S0514749224040137
- EDN: https://elibrary.ru/RYNANK
- ID: 278013
Дәйексөз келтіру
Толық мәтін
Аннотация
The article presents a method for the preparation of (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside from (1S,2S,3R,4R,5S)-methyl-3,5-di-O-benzyl-1,2-O-isopropylidene-α-L-talofuranoside by successive treatment of the latter with a 20% solution of hydrochloric acid in aqueous methanol, followed by treatment with benzoyl chloride in dry pyridine. A promising use of methyl (1S,2S,3R,4R,5S)-3,5-di-O-benzyl-2-O-benzoyl-α-L-talofuranoside for the synthesis of new modified nucleosides after its acetylation has also been shown.
Авторлар туралы
M. Khalikova
V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
Email: diavoly@mail.ru
Тәжікстан, ul. Ayni, 299/2, Dushanbe, 734063
U. Roziqov
V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
Email: diavoly@mail.ru
Тәжікстан, ul. Ayni, 299/2, Dushanbe, 734063
A. Skrylkova
St. Petersburg State Institute of Technology (Technical University)
Email: diavoly@mail.ru
Ресей, Moskovskii prosp., 26, St. Petersburg, 190013
D. Egorov
St. Petersburg State Institute of Technology (Technical University)
Хат алмасуға жауапты Автор.
Email: diavoly@mail.ru
ORCID iD: 0000-0003-3744-9306
Ресей, Moskovskii prosp., 26, St. Petersburg, 190013
S. Safarov
V. I. Nikitin Institute of Chemistry, National Academy of Sciences of Tajikistan
Email: diavoly@mail.ru
ORCID iD: 0000-0002-7193-6135
Тәжікстан, ul. Ayni, 299/2, Dushanbe, 734063
Әдебиет тізімі
- Fischer E., Piloty O. Ber. Dtsch. Chem. Ges. 1891, 24, 4214–4225. doi: 10.1002/cber.189102402322
- Eugenio F., Lourdes R. J. Biol. Chem. 2019, 294, 2249–2255. doi: 10.1074/jbc.CL119.007397.
- Jeanloz R.W., Fletcher H. G. Adv. Carbohydr. Chem. 1951, 6, 135–174. doi: 10.1016/S0096–5332(08)60066–1.
- Mao-Chin L., Mei-Zhen L., Diane E. M., Alan C. S. Nucleosid. Nucleotid. Nucleic. Acids. 2005, 24, 45–62. doi: 10.1081/NCN-46784.
- Hassan A.E.A., Abou-Elkhair R.A.I., Parker W. B., Allan P. W., Secrist III J. A. Bioorg. Chem. 2016, 65, 9–16. doi: 10.1016/j.bioorg.2015.12.006.
- Chhikara B.S., Parang K. Expert Opin. Drug Deliv. 2010, 7, 1399–1414. doi: 10.1517/17425247.2010.527330.
- Li Y., Li P., Li Y., Zhang R., Yu P., Ma Z., Kainov D. E., de Man R. A., Peppelenbosch M. P., Pan Q. Antivir. Res. 2020, 184, 104967. doi: 10.1016/j.antiviral.2020.104967.
- Cihák A. Oncology. 1974, 30, 405–422. doi 10.1159/ 000224981.
- Liliemark J. Clin. Pharmacokinet. 1997, 32, 120–131. doi: 10.2165/00003088–199732020–00003.
- Kantarjian H.M., O′Brien S., Cortes J., Giles F. J., Faderl S., Issa J. P., Garcia-Manero G., Rios M. B., Shan J., Andreeff M., Keating M., Talpaz M. Cancer. 2003, 98, 522–528. doi: 10.1002/cncr.11543.
- Allen-Mersh T.G., Earlam S., Fordy C., Abrams K., Houghton J. Lancet. 1994, 344, 1255–1260. doi: 10.1016/S0140–6736(94)90750–1.
- Tournilhac O., Cazin B., Leprètre S., Diviné M., Maloum K., Delmer A., Grosbois B., Feugier P., Maloisel F., Villard F., Villemagne B., Bastit D., Belhadj K., Azar N., Michallet M., Manhès G., Travade P. Blood. 2004, 103, 363–365. doi: 10.1182/blood-2003–05–1449.
- http://www.cancer.gov/cancertopics/druginfo/fda-nelarabine; Архивная копия от 11 сентября 2014 на Wayback Machine FDA Approval for Nelarabine.
- Wangsomboonsiri W., Mahasirimongkol S., Chantarangsu S., Kiertiburanakul S., Charoenyingwattana A., Komindr S., Thongnak C., Mushiroda T., Nakamura Y., Chantratita W., Sungkanuparph S. Clin. Infect. Dis 2010, 50, 597–604. doi: 10.1086/650003.
- Lai C.L., Leung N., Teo E. K., Tong M., Wong F., Hann H. W., Han S., Poynard T., Myers M., Chao G., Lloyd D., Brown N. A. Gastroenterology. 2005, 129, 528–536. doi: 10.1016/j.gastro.2005.05.053.
- Wilhelmus K.R. Cochrane Database Syst Rev. 2015, 1, CD002898. doi: 10.1002/14651858.CD002898.pub5
- Ko W.C., Rolain J. M., Lee N. Y., Chen P. L., Huang C. T., Lee P. I., Hsueh P. R. Int. J. Antimicrob. Agents. 2020, 55, 105933. doi: 10.1016/j.ijantimicag.2020.105933.
- Hassan A.E.A., Abou-Elkhair R.A.I., Parker W. B., Allan P. W., Secrist III J. A. Eur. J. Med. Chem. 2016, 108, 616–622. doi: 10.1016/j.ejmech.2015.12.029.
Қосымша файлдар
